A Randomized Trial of a 6-Week Course of Celecoxib on Proteinuria in Diabetic Kidney Disease

American Journal of Kidney Diseases

Volumn 50, Issue 6, 2007, Pages 946-951

  Sinsakul, Marvin ^a   Sika, Mohammed ^b   Rodby, Roger ^a   Middleton, John ^c   Shyr, Yu ^b   Chen, Heidi ^b   Han, Ernest ^b   Lehrich, Ruediger ^c   Clyne, Stephen ^b   Schulman, Gerald ^b   Harris, Raymond ^b   Lewis, Julia ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cyclooxygenase inhibitors; diabetic nephropathy; proteinuria

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CELECOXIB; CREATININE; CYCLOOXYGENASE 2 INHIBITOR; IRBESARTAN; PLACEBO; QUINAPRIL;

ACUTE KIDNEY FAILURE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CROSSOVER PROCEDURE; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CREATININE; CROSS-OVER STUDIES; CYCLOOXYGENASE INHIBITORS; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PILOT PROJECTS; PROTEINURIA; PYRAZOLES; SULFONAMIDES; TETRAHYDROISOQUINOLINES;

EID: 36248989657     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.09.005     Document Type: Article

References (20)

1. US Renal Data System. USRDS 2004 Annual Data Report (2004), The National Institutes of Health, National Institute of Diabetes, Digestive, and Kidney Diseases, Bethesda, MD
2. Lewis E.J., Hunsicker L.G., Bain R.P., et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
3. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
4. Harris R.C., and Breyer M.D. Update on cyclooxygenase-2 inhibitors. Clin J Am Soc Nephrol 1 (2006) 236-245
5. Wang J.L., Cheng H.F., Zhang M.Z., et al. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol 275 (1998) F613-F622
6. Cheng H.F., Wang C.J., Moeckel G.W., et al. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62 (2002) 929-939
7. Wang J.L., Cheng H.F., Sheppel S., et al. The cyclooxygenase-2 inhibitor, SC58326, decreases proteinuria and retards progression of glomerulosclerosis in the rat remnant kidney. Kidney Int 57 (2000) 2334-2342
8. Bergstein J.M. Prostaglandin inhibitors in the treatment of nephrotic syndrome. Pediatr Nephrol 5 (1991) 335-338
9. Sandhu G.K., and Heyneman C.A. Nephrotoxic potential of selective cyclooxygenase-2 inhibitors. Ann Pharmacother 38 (2004) 700-704
10. Bresalier R.S., Sandler R.S., Quan H., et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
11. Levey A.S., Coresh J., Greene T., et al. Expressing the MDRD Study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 16 (2005) 69A (abstr)
12. Zhang J., Ding E., and Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events. JAMA 296 (2006) 1619-1632
13. Horiba N., Kumano E., Watanabe T., et al. Subtotal nephrectomy stimulates cyclooxygenase 2 expression and prostacyclin synthesis in the rat remnant kidney. Nephron 91 (2002) 134-141
14. Vallon V., Kirschenmann D., Wead L.M., et al. Effect of chronic salt loading on kidney function in early and established diabetes mellitus in rats. J Lab Clin Med 130 (1997) 76-82
15. Thomson S.C., Deng A., Bao D., et al. Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes. J Clin Invest 107 (2001) 217-224
16. Heeg J.E., De Jong P.E., Vriesendorp R., et al. Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril. Am J Nephrol 10 (1990) 94-97
17. Chang I., and Harris R.C. Are all COX-2 inhibitors created equal?. Hypertension 45 (2005) 178-180
18. Frank D.H., Roe D.J., Chow H.S., et al. Effects of a high-selenium yeast supplement on celecoxib plasma levels: A randomized phase II trial. Cancer Epidemiol Biomarkers Prev 13 (2004) 299-303
19. Zhang J., Ding E., and Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrythmia events. JAMA 296 (2006) 1619-1632
20. Juurlink D., Mamdani M., Lee D., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551